VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next ...
Processa Pharmaceuticals, Inc. has announced a licensing agreement with Intact Therapeutics for PCS12852, a novel 5-HT4 receptor agonist aimed at treating gastroparesis and gastrointestinal motility ...
The acquisition transforms Processa’s pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029.
The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on September 2, 2025. The analyst firm set a price target for $1.00 expecting PCSA to fall to ...
Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.
) has been revised to $25.50 / share. This is an increase of 2,400.00% from the prior estimate of $1.02 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...
Good afternoon, ladies and gentlemen, and welcome to the Processa Pharmaceuticals Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode, and we will ...
ORLANDO, Fla., July 18, 2025 (Newswire.com) - RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small Stocks, ...
Thank you for standing by. My name is Demi, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Processa Pharmaceuticals' announced acquisition of Vidya ...
Processa completed a two-step merger with Vidya Therapeutics, Inc., establishing Vidya as a wholly owned subsidiary.
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results